Using CYP2D6 genotype to understand paroxetine-pimozide pharmacokinetics in man

被引：0
|
作者：
Foot, Elizabeth [1 ]
Briley, Linda [1 ]
McCarthy, Linda [1 ]
Moate, Rachel [1 ]
Reck, Brian [1 ]
Muir, Keith [1 ]
Stapleton, Carole [1 ]
Cox, Charles [1 ]
Dow, David [1 ]
Mehta, Nalini [1 ]
Latham, Ian [1 ]
Goodgame, Neil [1 ]
Vousden, Marika [1 ]
Nucci, Gianluca [1 ]
机构：
[1] GlaxoSmithKline Inc, Greenford, Middx, England
来源：
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS | 2006年 / 141B卷 / 07期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：786 / 786
页数：1
相关论文
共 50 条
  • [31] CYP2D6 and chlorpheniramine pharmacokinetics.
    Yasuda, SU
    Zannikos, P
    Young, AE
    Fried, KM
    Wainer, JW
    Woosley, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P7 - P7
  • [32] EFFECTS OF CYP2D6*10/*10 GENOTYPE ON THE PHARMACOKINETICS OF ATOMOXETINE AND ITS METABOLITES
    Park, J., I
    Choi, C., I
    Bae, J. W.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 65 - 65
  • [33] Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia
    Doki, Kosuke
    Homma, Masato
    Kuga, Keisuke
    Kusano, Kazutomi
    Watanabe, Shigeyuki
    Yamaguchi, Iwao
    Kohda, Yukinao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (11) : 919 - 926
  • [34] Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia
    Kosuke Doki
    Masato Homma
    Keisuke Kuga
    Kazutomi Kusano
    Shigeyuki Watanabe
    Iwao Yamaguchi
    Yukinao Kohda
    European Journal of Clinical Pharmacology, 2006, 62 : 919 - 926
  • [35] Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers
    Novalbos, Jesus
    Lopez-Rodriguez, Rosario
    Roman, Manuel
    Gallego-Sandin, Sonia
    Ochoa, Dolores
    Abad-Santos, Francisco
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (05) : 504 - 511
  • [36] Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
    Fukuda, T
    Yamamoto, I
    Nishida, Y
    Zhou, Q
    Ohno, M
    Takada, K
    Azuma, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (04) : 450 - 453
  • [37] Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia
    Kosuke Doki
    Masato Homma
    Keisuke Kuga
    Kazutomi Kusano
    Shigeyuki Watanabe
    Iwao Yamaguchi
    Yukinao Kohda
    European Journal of Clinical Pharmacology, 2007, 63 : 217 - 218
  • [38] Impact of CYP2D6 genotype and co-medication with paroxetine and clarithromycin on clomiphene metabolism in vivo
    Muerdter, T.
    Lehr, T.
    Igel, S.
    Kroener, P.
    Ganchev, B.
    Schaeffeler, E.
    Boehmer, G.
    Sonnenberg, M.
    Brauch, H.
    Kerb, R.
    Schwab, M.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S8 - S8
  • [39] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [40] Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers
    Özdemir, V
    Tyndale, RF
    Reed, K
    Herrmann, N
    Sellers, EM
    Kalow, W
    Naranjo, CA
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (05) : 472 - 475
12345